IMAB241220P2500
- 0.00
- 0.000.00%
I-Mab Newsroom
I-Mab to Participate at the Piper Sandler Healthcare Conference
I-Mab Third Quarter 2024 Earnings: US$0.25 Loss per Share (Vs US$0.57 Loss in 3Q 2023)
I-Mab's Third Quarter Results: Progress in Cancer Immunotherapies
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress
Express News | HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target
I-MAB Analyst Ratings
Express News | IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027
Express News | I-Mab: Estimated Cash Runway Into 2027, Based on $184.4 Mln in Cash & Cash Equivalents, & Short-Term Investments as of Sept30, 2024
I-Mab 3Q Loss $20.5M >IMAB
I-Mab 3Q Loss/Shr 11c >IMAB
I-Mab 3Q Rev $0.00 >IMAB
I-Mab | 6-K: Report of foreign private issuer (related to financial reporting)
I-Mab Biopharma GAAP EPS of -$0.11 Misses by $0.04
Express News | I-Mab: Qtrly Net Loss per Ads $0.25
Earnings Preview: I-Mab to Report Financial Results Pre-market on November 14
i-mab (IMAB.US) appoints Sean Fu as the company's Chief Executive Officer.
i-mab (IMAB.US) announced today that Dr. Sean (Xi-Yong) Fu, PhD, MBA, has been officially appointed as the Chief Executive Officer ("CEO") of the company, effective November 1, 2024. Dr. Fu has been serving as the interim CEO since July 15, 2024, and will continue as a member of the board of directors of I-Mab.
Express News | I-Mab - Appoints Sean Fu as CEO
Express News | I-Mab Appoints Sean Fu, Phd, MBA, as Chief Executive Officer
Express News | U.S.-Listed Shares of Chinese Firms Drop Premarket on Worries Over Growing U.S.-China Trade Tensions Under Trump Presidency